Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Chmielecki, Juliann, Foo, Jasmine, Oxnard, Geoffrey R., Hutchinson, Katherine, Ohashi, Kadoaki, Somwar, Romel, Wang, Lu, Amato, Katherine R., Arcila, Maria, Sos, Martin L., Socci, Nicholas D., Viale, Agnes, de Stanchina, Elisa, Ginsberg, Michelle S., Thomas, Roman K., Kris, Mark G., Inoue, Akira, Ladanyi, Marc, Miller, Vincent A., Michor, Franziska, Pao, William
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500629/
https://ncbi.nlm.nih.gov/pubmed/21734175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3002356
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares